Advice
Following a full submission.
Sorafenib (Nexavar) is not recommended for use within NHS Scotland for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alfa or interleukin- 2 based therapy or are considered unsuitable for such therapy.
Sorafenib has been compared with best supportive care and has been shown to increase progression-free survival, though the impact on overall survival is uncertain.
The cost effectiveness of sorafenib has not been demonstrated.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- sorafenib 200mg tablets (Nexavar)
- SMC ID:
- 321/06
- Indication:
- Renal cell carcinoma
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 13 November 2006